Tocagen, a clinical-stage, cancer-selective gene therapy company, will be expanding its phase 2/3 clinical trial, Toca 5, to Canada, after completing its initial phases in the U.S. in 2015. The focus of this study is to improve overall survival for patients with first or second recurrence of glioblastoma and anaplastic astrocytoma who are undergoing surgery.
Researchers will compare the combination of Toca 511 and Toca FC (cancer-selective gene therapies) with standard of care treatments (chemotherapy or antiangiogenic therapies) on patients with high-grade glioma to identify Tocagen’s capacity to improve overall survival.
Kevin Petrecca, M.D., Ph.D., associate professor at the Brain Tumour Research Center at McGill University’s Montreal Neurological Institute and Hospital says, “Tocagen’s innovative approach to fighting recurrent brain cancer using cancer-selective gene therapy is the kind of cutting-edge investigational treatment that we want to offer our patients at our site.”
To read the full study, click here.